We recently published a list of S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment. In this article, we are ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best ...

Newly off-patent Stelara sales declined less than expected, but JNJ is facing in-creased competition in 2025—before its ...

For investors seeking a balance of risk management and income, a mix of low-volatility, high-dividend stocks can be a smart ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Coca-Cola Co. Read MarketBeat.com (Ryan Hasson)'s latest article on Investing.com ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price objective cut by research analysts at The Goldman Sachs Group from $43.00 to $38.00 in a report released on Monday,Benzinga ...

DTD offers a dividend-weighted portfolio with significant exposure to technology. Read more to see my recommendation for the ...

"The demand environment remains consistent with our view of a gradual recovery in 2025," said CEO Satish Dhanasekaran.